<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911204-0041</DOCNO><DOCID>911204-0041.</DOCID><HL>   Business Brief -- MedImmune Inc.:   Accord Is Set With Merck   On Developing Antibodies</HL><DATE>12/04/91</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   MEDI MRK</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>BIOTECHNOLOGY (BTC)DRUG MANUFACTURERS (DRG)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><RE>MARYLAND (MD)NEW JERSEY (NJ)NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   MedImmune Inc. said it reached a definitive agreement withMerck andamp; Co. to collaborate in developing MedImmune'smonoclonal antibodies for preventing infection by the AIDSvirus.   Merck, based in Rahway, N.J., agreed to pay MedImmune, ofGaithersburg, Md., about $13 million for development work onsuch antibodies over the next three years, beginning in thefourth quarter. MedImmune will retain rights to co-promotewith Merck any products resulting from the program.Monoclonal antibodies are versions of naturally occurringimmune molecules that, when tailored to target a portion ofthe human immunodeficiency virus (HIV type 1), have shownpromise in blocking infection by the virus. The virus causesthe fatal acquired immune deficiency syndrome.</LP><TEXT>   Shares of both companies rose yesterday. In New York StockExchange trading, Merck was quoted at $150.25 a share, up$2.125. In national over-the-counter trading, MedImmune rose$3 to close at $38.</TEXT></DOC>